secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001437749-26-009063
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals announces $10M public offering of stock and warrants
---------------------------------------------------------------------------

- Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.
- Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.
- Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.
- Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/rvph20260319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer